Research Article

Detection of IDH mutations in cerebrospinal fluid: A discussion of liquid biopsy in neuropathology

Ming Lee*, Gek San Tan, Chee Kian Tham and Kiat-Hon Tony Lim

Published: 17 September, 2020 | Volume 4 - Issue 1 | Pages: 011-023

Isocitrate dehydrogenase (IDH) mutations are a common event in secondary glioblastoma multiforme and lower-grade adult infiltrative astrocytomas and independently confer a better prognosis [1,2]. These are highly conserved mutations during glioma progression and thus also a useful diagnostic marker amenable to modern molecular sequencing methods. These mutations can even be detected in sites distant from the primary tumour. We use an illustrative case of a patient with radiologically suspected recurrent astrocytoma and negative histology, but positive IDH-mutated tumour DNA detected within CSF. Our results demonstrated the usefulness of liquid biopsy for recurrent glioma within the context of equivocal or negative histopathological results, whilst also showing the ability to detect a de-novo IDH-2 mutation not present in the previous resection. Building on this ‘proof-of-concept’ result, we also take the opportunity to briefly review the current literature describing the various liquid biopsy substrates available to diagnose infiltrative gliomas, namely the study of circulating tumour DNA, circulating tumour cells, and extracellular vesicles. We outline the current challenges and prospects of liquid biopsies in these tumours and suggest that more studies are required to overcome these challenges and harness the potential benefits of liquid biopsies in guiding our management of gliomas

Read Full Article HTML DOI: 10.29328/journal.apcr.1001018 Cite this Article Read Full Article PDF


  1. Hartmann C, Hentschel B, Tatagiba M, Schramm J, Schnell O, et al. Molecular Markers in Low-Grade Gliomas: Predictive or Prognostic? Clin Cancer Res. 2011; 17: 4588–4599. Pubmed: http://www.ncbi.nlm.nih.gov/pubmed/21558404
  2. Reuss DE, Mamatjan Y, Schrimpf D, Capper D, Hovestadt V, et al. IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO. Acta Neuropathol. 2015; 129: 867–873. PubMed: https://pubmed.ncbi.nlm.nih.gov/25962792/
  3. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016; 131: 803–820. PubMed: https://pubmed.ncbi.nlm.nih.gov/27157931/
  4. Sahm F, Schrimpf D, Jones DTW, Meyer J, Kratz A, et al. Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets. Acta Neuropathol. 2016; 131: 903–910. PubMed: https://pubmed.ncbi.nlm.nih.gov/26671409
  5. Li KW, Ng HK. How does one do next-generation sequencing for brain tumors in the clinical laboratories? Glioma. 2018; 1: 149.
  6. Kim H, Zheng S, Amini SS, Virk SM, Mikkelsen T, et al. Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution. Genome Res. 2015; 25: 316–227. PubMed: https://pubmed.ncbi.nlm.nih.gov/25650244/
  7. Hartmann C, Hentschel B, Simon M, Westphal M, Schackert G, et al. Long-term survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations. Clin Cancer Res. 2013; 19: 5146–5157. PubMed: https://pubmed.ncbi.nlm.nih.gov/23918605/
  8. Sanson M, Marie Y, Paris S, Idbaih A, Laffaire J, et al. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol. 2009; 27: 4150–4154. PubMed: https://pubmed.ncbi.nlm.nih.gov/19636000/
  9. Yan H, Williams D, Jin G, Mclendon R, Rasheed BA, et al. IDH1 and IDH2 Mutations in Gliomas. N Engl J Med. 2009; 360: 765–773. PubMed: https://pubmed.ncbi.nlm.nih.gov/19228619/
  10. Loo HK, Mathen P, Lee J, Camphausen K. Circulating biomarkers for high-grade glioma. Biomark Med. 2019; 13: 161–165. PubMed: https://pubmed.ncbi.nlm.nih.gov/30806515/
  11. Brat DJ, Verhaak RGW, Aldape KD, Yung WKA, Salama SR, et al. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med. 2015; 372: 2481–2498. PubMed: http://www.nejm.org/doi/10.1056/NEJMoa1402121
  12. Wang SR, Malik S, Tan IB, Chan YS, Hoi Q, et al. Technical Validation of a Next-Generation Sequencing Assay for Detecting Actionable Mutations in Patients with Gastrointestinal Cancer. J Mol Diagnostics. 2016; 18: 416–424. PubMed: https://pubmed.ncbi.nlm.nih.gov/26970585/
  13. Horbinski C. What do we know about IDH1/2 mutations so far, and how do we use it? Acta Neuropathol. 2013; 125: 621–636. PubMed: https://pubmed.ncbi.nlm.nih.gov/23512379/
  14. Kruser TJ, Mehta MP, Robins HI. Pseudoprogression after glioma therapy: A comprehensive review. Expert Rev Neurother. 2013; 13: 389–403. PubMed: https://pubmed.ncbi.nlm.nih.gov/23545054/
  15. Westphal M, Lamszus K. Circulating biomarkers for gliomas. Nat Rev Neurol. 2015;11: 556–566. PubMed: https://pubmed.ncbi.nlm.nih.gov/26369507/
  16. Cabel L, Proudhon C, Gortais H, Loirat D, Coussy F, et al. Circulating tumor cells: clinical validity and utility. Int J Clin Oncol. 2017; 22: 421–430. PubMed: https://pubmed.ncbi.nlm.nih.gov/28238187/
  17. Choon AW T. Clinical Utility of Circulating Tumor Cells – A Clinician’s Current View. Hematol Med Oncol. 2017; 2: 1–9.
  18. Sottoriva A, Spiteri I, Piccirillo SGM, Touloumis A, Collins VP, et al. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc Natl Acad Sci. 2013; 110: 4009–1014. PubMed: https://www.pnas.org/content/110/10/4009
  19. MacArthur KM, Kao GD, Chandrasekaran S, Alonso-Basanta M, Chapman C, et al. Detection of brain tumor cells in the peripheral blood by a telomerase promoter-based assay. Cancer Res. 2014; 74: 2152–2159. PubMed: https://pubmed.ncbi.nlm.nih.gov/24525740/
  20. Kros JM, Mustafa DM, Dekker LJM, Smitt PAES, Luider TM, et al. Circulating glioma biomarkers. Neuro Oncol. 2015; 17: 343–360. PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4483097/
  21. Saenz-Antoñanzas A, Auzmendi-Iriarte J, Carrasco-Garcia E, Moreno-Cugnon L, Ruiz I, et al. Liquid biopsy in glioblastoma: Opportunities, applications and challenges. Cancers (Basel). 2019; 11: 950. PubMed: https://pubmed.ncbi.nlm.nih.gov/31284524/
  22. Müller Bark J, Kulasinghe A, Chua B, Day BW, Punyadeera C. Circulating biomarkers in patients with glioblastoma. Br J Cancer. 2020; 122: 295-305.. PubMed: https://pubmed.ncbi.nlm.nih.gov/31666668/
  23. Orlic L, Sladoje-Martinovic B, Mikolasevic I, Zupan Z, Racki S. Patients with primary brain tumors as organ donors. BANTAO J. 2015; 13: 34–38.
  24. Müller C, Holtschmidt J, Auer M, Heitzer E, Lamszus K, et al. Cancer: Hematogenous dissemination of glioblastoma multiforme. Sci Transl Med. 2014; 6: 247ra101. PubMed: https://pubmed.ncbi.nlm.nih.gov/25080476/
  25. Jackson D. Rapp HM, Schneiderhan TM, Michael Sabel Anne Hayman Axel SchererPatric Kröpil , Wilfried Budach , Usha Kretschmar , Peter Arne Gerber Sujit Prabhu , Lawrence E. Ginsberg Edwin Bölke CM. Glioblastoma Multiforme Metastasis Outside the CNS: Three Case Reports and Possible Mechanisms of Escape Introduction. J Clin Oncol. 2012; 29: 2011–2013.
  26. Ferreira MM, Ramani VC, Jeffrey SS. Circulating tumor cell technologies. Mol Oncol. 2016; 10: 374–394. www.nature.com/npjprecisiononcology%0Ahttp://www.nature.com/articles/s41698-017-0028-8
  27. Lombard A, Goffart N, Rogister B. Glioblastoma circulating cells: Reality, trap or illusion? Stem Cells Int. 2015; 2015. PubMed: https://pubmed.ncbi.nlm.nih.gov/26078762/
  28. Krol I, Castro-Giner F, Maurer M, Gkountela S, Szczerba BM, et al. Detection of circulating tumour cell clusters in human glioblastoma. Br J Cancer. 2018; 119: 487–491. PubMed: https://pubmed.ncbi.nlm.nih.gov/30065256/
  29. Piccioni DE, Lanman RB, Nagy RJ, Talasaz A, Pingle SC, et al. Analysis of cell-free circulating tumor DNA in patients with glioblastoma and other primary brain tumors. J Clin Oncol. 2015; 33: 11072–11072. https://ascopubs.org/doi/10.1200/jco.2015.33.15_suppl.11072
  30. Wang Y, Springer S, Zhang M, McMahon KW, Kinde I, et al. Detection of tumor-derived DNA in cerebrospinal fluid of patients with primary tumors of the brain and spinal cord. Proc Natl Acad Sci. 2015; 112: 9704–9709. PubMed: https://pubmed.ncbi.nlm.nih.gov/26195750/
  31. Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, et al. Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies. Sci Transl Med. 2014; 62 24ra24-224ra24. http://stm.sciencemag.org/cgi/doi/10.1126/scitranslmed.3007094
  32. Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008; 14: 985–990. PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2820391/ b
  33. Diaz LA, Bardelli A. Liquid biopsies: Genotyping circulating tumor DNA. J Clin Oncol. 2014; 32: 579–586. PubMed: https://pubmed.ncbi.nlm.nih.gov/24449238/
  34. Chen WW, Balaj L, Liau LM, Samuels ML, Kotsopoulos SK, et al. Beaming and droplet digital pcr analysis of mutant idh1 mrna in glioma patient serum and cerebrospinal fluid extracellular vesicles. Mol Ther - Nucleic Acids. 2013; 2: e109. PubMed: https://pubmed.ncbi.nlm.nih.gov/23881452/
  35. Ghosh RK, Pandey T, Dey P. Liquid biopsy: A new avenue in pathology. Cytopathology. 2019; 30: 138–143. PubMed: https://pubmed.ncbi.nlm.nih.gov/30485558/
  36. Bertero L, Siravegna G, Rudà R, Soffietti R, Bardelli A, et al. Review: Peering through a keyhole: liquid biopsy in primary and metastatic central nervous system tumours. Neuropathol Appl Neurobiol. 2019; 45: 655–670. PubMed: https://pubmed.ncbi.nlm.nih.gov/30977933
  37. Schwaederle M, Chattopadhyay R, Kato S, Fanta PT, Kimberly C, et al. Genomic alterations in circulating tumor DNA from diverse cancer patients identified by next-generation sequencing. Cancer Res. 2017; 77: 5419–5427. PubMed: https://pubmed.ncbi.nlm.nih.gov/28807936/
  38. Piccioni DE, Achrol AS, Kiedrowski LA, Banks KC, Boucher N, et al. Analysis of cell-free circulating tumor DNA in 419 patients with glioblastoma and other primary brain tumors. CNS Oncol. 2019; 8: CNS34. PubMed: https://pubmed.ncbi.nlm.nih.gov/30855176/
  39. Brennan CW, Verhaak RGW, McKenna A, Campos B, Noushmehr H, et al. The Somatic Genomic Landscape of Glioblastoma. Cell. 2013; 155: 462–477. https://linkinghub.elsevier.com/retrieve/pii/S0092867413012087
  40. WANG Z, JIANG W, WANG Y, GUO Y, CONG Z, et al. MGMT promoter methylation in serum and cerebrospinal fluid as a tumor-specific biomarker of glioma. Biomed Reports. 2015; 3: 543–548. PubMed: https://pubmed.ncbi.nlm.nih.gov/26171163/
  41. De Mattos-Arruda L, Mayor R, Ng CKY, Weigelt B, Martínez-Ricarte F, et al. Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. Nat Commun. 2015; 6: 8839. PubMed: https://pubmed.ncbi.nlm.nih.gov/26554728/
  42. Miller AM, Shah RH, Pentsova EI, Pourmaleki M, Briggs S, et al. Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid. Nature. 2019; 565: 654–658. PubMed: https://pubmed.ncbi.nlm.nih.gov/30675060/
  43. Li I, Nabet BY. Exosomes in the tumor microenvironment as mediators of cancer therapy resistance. Mol Cancer. 2019; 18: 32. PubMed: https://pubmed.ncbi.nlm.nih.gov/30823926/
  44. Skog J, Würdinger T, van Rijn S, Meijer DH, Gainche L, et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol. 2008; 10: 1470–1476. PubMed: https://pubmed.ncbi.nlm.nih.gov/19011622/
  45. Shao H, Chung J, Balaj L, Charest A, Bigner DD, et al. Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy. Nat Med. 2012; 18: 1835–1840. http://www.nature.com/articles/nm.2994
  46. Banelli B, Forlani A, Allemanni G, Morabito A, Pistillo MP, et al. MicroRNA in glioblastoma: An overview. Int J Genomics. 2017; 2017: 7639084. PubMed: https://pubmed.ncbi.nlm.nih.gov/29234674/
  47. Bader AG, Brown D, Winkler M. The Promise of MicroRNA Replacement Therapy. Cancer Res. 2010; 70: 7027–7030. PubMed: https://pubmed.ncbi.nlm.nih.gov/20807816/
  48. Li CCY, Eaton SA, Young PE, Lee M, Shuttleworth R, et al. Glioma microvesicles carry selectively packaged coding and noncoding RNAs which alter gene expression in recipient cells. RNA Biol. 2013; 10: 1333–1344. PubMed: https://pubmed.ncbi.nlm.nih.gov/23807490/
  49. Shi R, Wang PY, Li XY, Chen JX, Li Y, et al. Exosomal levels of miRNA-21 from cerebrospinal fluids associated with poor prognosis and tumor recurrence of glioma patients. Oncotarget. 2015; 6: 26971–26981. PubMed: https://pubmed.ncbi.nlm.nih.gov/26284486/
  50. Qu S, Guan J, Liu Y. Identification of microRNAs as novel biomarkers for glioma detection: A meta-analysis based on 11 articles. J Neurol Sci. 2015; 348: 181–187. PubMed: https://pubmed.ncbi.nlm.nih.gov/25510379/
  51. Zhang W, Zhang J, Hoadley K, Kushwaha D, Ramakrishnan V, et al. MiR-181d: Predictive glioblastoma biomarker that downregulates MGMT expression. Neuro Oncol. 2012; 14: 712–719. PubMed: https://pubmed.ncbi.nlm.nih.gov/22570426/
  52. Verbeek B, Southgate TD, Gilham DE, Margison GP. O6-Methylguanine-DNA methyltransferase inactivation and chemotherapy. Br Med Bull. 2008; 85: 17–33. PubMed: https://pubmed.ncbi.nlm.nih.gov/18245773/
  53. Tang K, Gardner S, Snuderl M. The Role of Liquid Biopsies in Pediatric Brain Tumors. J Neuropathol Exp Neurol. 2020; 79: 934-940. PubMed: https://pubmed.ncbi.nlm.nih.gov/32766689/
  54. Tuxen MK, Sölétormos G, Dombernowsky P. Serum tumour marker CA 125 in monitoring of ovarian cancer during first-line chemotherapy. Br J Cancer. 2001; 84: 1301–1307. PubMed: https://pubmed.ncbi.nlm.nih.gov/11355938/
  55. Ito K, Hibi K, Ando H, Hidemura K, Yamazaki T, et al. Usefulness of analytical CEA doubling time and half-life time for overlooked synchronous metastases in colorectal carcinoma. Jpn J Clin Oncol. 2002; 32: 54–58. PubMed: https://pubmed.ncbi.nlm.nih.gov/11948229/
  56. Shinozaki M, O’Day SJ, Kitago M, Amersi F, Kuo C, et al. Utility of circulating B-RAF DNA mutation in serum for monitoring melanoma patients receiving biochemotherapy. Clin Cancer Res. 2007; 13: 2068–2074. PubMed: https://pubmed.ncbi.nlm.nih.gov/17404088/
  57. Dawson SJ, Tsui DWY, Murtaza M, Biggs H, Rueda OM, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med. 2013; 368: 1199–1209. PubMed: https://pubmed.ncbi.nlm.nih.gov/23484797/
  58. Thomsen CEB, Appelt AL, Andersen RF, Lindebjerg J, Jensen LH, et al. The prognostic value of simultaneous tumor and serum RAS/RAF mutations in localized colon cancer. Cancer Med. 2017; 6: 928–936. PubMed: https://pubmed.ncbi.nlm.nih.gov/28378527/
  59. Rudà R, Reifenberger G, Frappaz D, Pfister SM, Laprie A, et al. EANO guidelines for the diagnosis and treatment of ependymal tumors. Neuro Oncol. 2018; 20: 445–456. PubMed: https://pubmed.ncbi.nlm.nih.gov/29194500/
  60. Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell. 2017; 168: 707–723. PubMed: https://pubmed.ncbi.nlm.nih.gov/28187290/
  61. Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature. 2012; 486: 532–536. PubMed: https://pubmed.ncbi.nlm.nih.gov/22722830/
  62. Camidge DR, Pao W, Sequist LV. Acquired resistance to TKIs in solid tumours: Learning from lung cancer. Nat Rev Clin Oncol. 2014; 11: 473–481. PubMed: https://pubmed.ncbi.nlm.nih.gov/24981256/
  63. Serrano C, George S, Valverde C, Olivares D, García-Valverde A, et al. Novel Insights into the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors. Target Oncol. 2017; 12: 277–288. PubMed: https://pubmed.ncbi.nlm.nih.gov/28478525/
  64. Murtaza M, Dawson SJ, Tsui DWY, Gale D, Forshew T, et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature. 2013; 497: 108–112. PubMed: https://pubmed.ncbi.nlm.nih.gov/23563269/
  65. Higgins MJ, Jelovac D, Barnathan E, Blair B, Slater S, et al. Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood. Clin Cancer Res. 2012; 18: 3462–3469. PubMed: https://pubmed.ncbi.nlm.nih.gov/22421194/
  66. Akers JC, Ramakrishnan V, Yang I, Hua W, Mao Y, et al. Optimizing preservation of extracellular vesicular miRNAs derived from clinical cerebrospinal fluid. Cancer Biomarkers. 2016; 17: 125–132. PubMed: https://pubmed.ncbi.nlm.nih.gov/27062568/
  67. Fritz JV, Heintz-Buschart A, Ghosal A, Wampach L, Etheridge A, et al. Sources and Functions of Extracellular Small RNAs in Human Circulation. Annu Rev Nutr. 2016; 36: 301–336. PubMed: https://pubmed.ncbi.nlm.nih.gov/27215587/
  68. Akers JC, Ramakrishnan V, Nolan JP, Duggan E, Fu CC, et al. Comparative analysis of technologies for quantifying extracellular vesicles (EVs) in clinical cerebrospinal fluids (CSF). PLoS One. 2016; 11: e0149866. PubMed: https://pubmed.ncbi.nlm.nih.gov/26901428/
  69. Gao F, Cui Y, Jiang H, Sui D, Wang Y, et al. Circulating tumor cell is a common property of brain glioma and promotes the monitoring system. Oncotarget. 2016; 7: 71330–71340. PubMed: https://pubmed.ncbi.nlm.nih.gov/27517490/
  70. Kros JM, Huizer K, Hernández-Laín A, Marucci G, Michotte A, et al. Evidence-based diagnostic algorithm for glioma: Analysis of the results of pathology panel review and molecular parameters of EORTC 26951 and 26882 trials. J Clin Oncol. 2015; 33: 1943–1950. PubMed: https://pubmed.ncbi.nlm.nih.gov/25918297/


Figure 1

Figure 1

Figure 1

Figure 2

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More